Our Doctors First Act of 2026
Summary
HR8943 (Our Doctors First Act) would ban Medicare GME payments for non-citizen residents, imposing penalties on hospitals. The bill is in early committee stage with no companion Senate bill, making passage unlikely. For-profit hospital operators HCA, UHS, and THC face modest operational risk if enacted, but no near-term market impact.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill is early-stage with low passage probability
- 2.No direct funding or tax changes; restricts existing Medicare GME payments
- 3.For-profit hospital operators face modest operational risk if enacted
Market Implications
The bill has minimal market implications at this stage. If it gains traction, for-profit hospital operators like HCA, UHS, and THC could face increased labor costs from replacing non-citizen residents, but the effect on earnings would be small (less than 1% of revenue). No bullish signals for any sector.
Full Analysis
HR8943 was introduced on May 20, 2026 by Rep. Steube (R-FL) and referred to the Ways and Means and Energy and Commerce Committees. The bill amends the Social Security Act to prohibit Medicare from paying for graduate medical education costs attributable to non-citizen residents, effective one year after enactment. Hospitals that knowingly count non-citizen residents face escalating civil monetary penalties. The bill is in early stage with no Senate companion, and the 119th Congress has limited time remaining. The money trail is zero: the bill does not authorize or appropriate any funding; it restricts existing Medicare GME payments. Structural winners are US-citizen medical residents who may face less competition for slots, but no public company benefits directly. Losers are teaching hospitals that rely on non-citizen residents, particularly large academic medical centers and for-profit chains with teaching programs. HCA, UHS, and THC have exposure, but the impact is small relative to their revenue (HCA's FY2025 revenue was ~$70B; GME payments are a fraction). No real market data is provided for these tickers, so no price trend analysis is possible. The legislative timeline is uncertain: the bill must pass both committees, the House, the Senate, and be signed into law. With a Republican sponsor and divided government, passage probability is low.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Prohibition on Medicare graduate medical education (GME) payments for non-citizen residents, with civil monetary penalties for hospitals that count them.
Who must act
Hospitals receiving Medicare GME payments under Section 1886(h) of the Social Security Act.
What happens
Hospitals must exclude non-citizen residents from GME cost reports or face penalties equal to 25% of attributable payment for first violation, increasing for subsequent violations.
Stock impact
HCA operates 186+ hospitals with teaching programs; non-citizen residents (estimated 10-15% of GME residents nationally) would need replacement with US citizens, potentially increasing labor costs or reducing residency slots, but HCA's scale and ability to recruit domestically mitigates impact.
What the bill does
Same prohibition on Medicare GME payments for non-citizen residents.
Who must act
Hospitals receiving Medicare GME payments.
What happens
Exclusion of non-citizen residents from GME cost reports; penalties for non-compliance.
Stock impact
UHS operates 400+ acute care hospitals and behavioral health facilities; teaching hospitals within its network may face similar staffing constraints, but UHS's focus on behavioral health (lower GME reliance) reduces exposure relative to large academic medical centers.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
VA Mental Health Outreach and Engagement Act
H–1Bs for Physicians and the Healthcare Workforce Act
Restoring Overtime Pay Act of 2026
To amend the Employee Retirement Income Security Act of 1974 to allow health marketplace pools to be deemed an employer under section 3(5) of such Act for purposes of offering a group health plan or group health insurance coverage, and for other purposes.
Legalizing Premium Health Care Act of 2026
Executive Order: Promoting Efficiency, Accountability, and Performance in Federal Contracting
Executive Order: Accelerating Medical Treatments for Serious Mental Illness
ADVANCED TECHNOLOGY INTERNATIONAL: $304M Department of Health and Human Services Contract
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Accelerating Medical Treatments for Serious Mental Illness
This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.